Genocea Banking On Success With Herpes Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
Having raised $61 million in its February IPO, Genocea hopes 2015 will be another transformative year for the company, as it expects Phase II data for its herpes simplex virus vaccine, a potential first-in-class product.
You may also be interested in...
Genocea Gets An Injection Of Capital As Early-Stage Studies Progress
The vaccine developer tapped investors for a third round of financing as its lead programs begin clinical trials.
Genocea Biosciences Inc.
Genocea Biosciences Inc. is one of a growing number of companies betting that it can stimulate the body’s T-cell response against particular antigens, and so create vaccines against pathogens never before bested by man, such as malaria, herpes and chlamydia. Like others working to develop new vaccines, Genocea suspects that the ability to conjure cellular immunity on demand could offer not only prophylaxis, but also therapeutic options to individuals already infected by pathogens. Many believe that T-cell-stimulating vaccines could eventually help people whose own cells have become cancerous.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.